Press releases
Latest press releases and new announcements from Adcendo
Press materials
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Copenhagen, Denmark,...
GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
GlyTherix Ltd (“GlyTherix”), an Australian immune-oncology company today announced an MTA & Option License with Adcendo ApS (“Adcendo”), a Danish biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules
Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field
Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
The poster presentation highlights the preclinical evaluation of several of Adcendo´s ADC candidates for the treatment of osteosarcoma
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
Building the team with experienced biotech experts and renowned leaders in the ADC field and
Underscores company’s commitment to progressing lead program on novel ADC target uPARAP
Adcendo Appoints Michael Pehl as Chief Executive Officer
Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record
Adcendo Series A Press Release
Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers